Skip to content

Levamizol effect in reducing relapse rate of nephrotic syndrome

Study of levamizole effect in reduction of relapse rate in children with frequently relapsing/steroid dependent idiopathic nephrotic syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201106066589N2
Enrollment
30
Registered
2011-08-15
Start date
2010-09-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nephrotic syndrome.

Interventions

In patients with relapse of NS,the relapse episode is controled with prednisolone 40 mg/m2/day for 7-10 days and then levamisole 2.5 mg/m2/every other day is administered while prednisolone is tapered
Treatment - Drugs

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: idiopathic nephrotic syndrome;frequent relapses or dependency to steroid;age 1-14 years old. Exclusion criteria: the patients who consume levamizole less than 6 months;need to start other immunosupressive drugs to control the relapses.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Rate of relapses of nephrotic syndrom. Timepoint: during the whole period of study. Method of measurement: in relapses/year.;Cumulative dose of prednisolone. Timepoint: durig the whole period of the study. Method of measurement: in mg/kg body weight/year.

Secondary

MeasureTime frame
Neutropenia. Timepoint: every 4 months. Method of measurement: CBC.;Liver enzymes elevation. Timepoint: every 4 months. Method of measurement: AST,ALT.;Seizure. Timepoint: during the study period. Method of measurement: clinical.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Abolhassan Seyedzadeh

Kermanshah University of Medical Sciences

asayedzadeh@kums.ac.ir+98 83 1427 6301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026